Kaken Pharmaceutical Co (TSE:4521) Cyclically Adjusted Revenue per Share: 円2,398.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4521 Kaken Pharmaceutical Co Ltd TSE:4521
62 GF Score
Price 円4,015.00
GF Value 円3,974.43
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Kaken Pharmaceutical Co TSE:4521 -0.62% 62 Cyclically Adjusted Revenue per Share is 円2,398.35 as of Mar. 2026. GuruFocus rates TSE:4521 with a GF Score™ of 62/100 and a GF Value™ of 円3,974.43 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円507.874. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円2,398.35 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Kaken Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was -2.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kaken Pharmaceutical Co was 2.30% per year. The lowest was 0.60% per year. And the median was 1.20% per year.

As of today (2026-08-14), Kaken Pharmaceutical Co's current stock price is 円4015.00. Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円2,398.35. Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kaken Pharmaceutical Co was 2.99. The lowest was 1.34. And the median was 1.81.


Kaken Pharmaceutical Co  (TSE:4521) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4015.00/2398.35
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kaken Pharmaceutical Co was 2.99. The lowest was 1.34. And the median was 1.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,302.83 2,354.86 2,377.51 2,462.17 2,398.35

Kaken Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,462.17 2,449.38 2,434.90 2,420.12 2,398.35

TSE:4521 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4521
62GF Score
Kaken Pharmaceutical Co Ltd TSE:4521
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kaken Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kaken Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=507.874/112.7000*112.7000
=507.874

Current CPI (Mar. 2026) = 112.7000.

Kaken Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 633.664 98.100 727.971
201609 626.745 98.000 720.757
201612 646.911 98.400 740.923
201703 563.369 98.100 647.214
201706 611.472 98.500 699.623
201709 615.996 98.800 702.659
201712 670.412 99.400 760.115
201803 534.251 99.200 606.957
201806 599.062 99.200 680.588
201809 588.002 99.900 663.342
201812 631.024 99.700 713.304
201903 543.406 99.700 614.261
201906 562.935 99.800 635.699
201909 584.793 100.100 658.403
201912 641.922 100.500 719.847
202003 489.607 100.300 550.137
202006 464.322 99.900 523.815
202009 483.383 99.900 545.318
202012 528.574 99.300 599.902
202103 466.968 99.900 526.800
202106 481.701 99.500 545.605
202109 503.977 100.100 567.415
202112 506.062 100.100 569.762
202203 484.584 101.100 540.184
202206 481.300 101.800 532.834
202209 496.216 103.100 542.420
202212 500.467 104.100 541.812
202303 464.603 104.400 501.540
202306 484.362 105.200 518.894
202309 477.529 106.200 506.756
202312 488.883 106.800 515.891
202403 458.384 107.200 481.902
202406 482.056 108.200 502.105
202409 874.495 108.900 905.010
202412 650.032 110.700 661.776
202503 472.853 111.100 479.663
202506 496.395 111.700 500.839
202509 539.838 112.000 543.212
202512 481.605 113.000 480.326
202603 507.874 112.700 507.874

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円2,398.35 mean?
Kaken Pharmaceutical Co (TSE:4521) has a Cyclically Adjusted Revenue per Share of 円2,398.35 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Kaken Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円2,398.35. Overall, Kaken Pharmaceutical Co has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Kaken Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円2,398.35 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円2,398.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,974.43, compared to a current price of 円4,015.00 — trading 1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円2,398.35. Kaken Pharmaceutical Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Cyclically Adjusted Revenue per Share is 円2,398.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?

Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued. The current stock price of 円4,015.00 is trading 1% above its estimated GF Value™ of 円3,974.43. GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4521:

  • Cyclically Adjusted Revenue per Share: 円2,398.35
  • GF Value™: 円3,974.43 vs. price of 円4,015.00 (1% above fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kaken Pharmaceutical Co Business Description

Address 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
62GF Score

Get the complete analysis for TSE:4521

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円4,015.00
Price
円3,974.43
GF Value